Clovis Oncology (CLVS) Trades Higher in Sympathy with TESARO (TSRO)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Gains in Clovis Oncology (NASDAQ: CLVS) Monday were tied to data from PARP inhibitor peer TESARO (NASDAQ: TSRO). Earlier TESARO and ENGOT, the European Network for Gynaecological Oncological Trial groups, announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress.
Shares of TESARO surged over 20%, while Clovis gained about 8%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Acacia Communications (ACIA) Mentioned as Short in Lakewood Capital's Q3 Letter - Bloomberg
- Cypress Semiconductor (CY) Gains Ahead of Next Week's Print
- Rite Aid (RAD) volatility spikes on call put ratio of 1 call to 3.6 puts on Walgreens deal closure uncertainty
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!